RIN1 and ABL2

  • Number of citations of the paper that reports this interaction (PMID 15886098)
  • 29
  • Data Source:
  • HPRD (in vivo)

RIN1

ABL2

Gene Name Ras and Rab interactor 1 ABL proto-oncogene 2, non-receptor tyrosine kinase
Image No pdb structure
Gene Ontology Annotations Cellular Component
Molecular Function
Biological Process
Pathways
Drugs
Diseases
GWAS
Protein-Protein Interactions 15 interactors: ABL1 ABL2 CALCOCO2 ERBB2 ERBB3 HRAS LZTS2 MLLT4 RAB5A RAB5B RALGDS RRAS2 YWHAB YWHAE YWHAZ 25 interactors: ABL1 BCR C15orf48 CAT CRK DOK1 EGFR EPHB2 ERBB2 ERBB3 ERBB4 FBXO38 GPX1 GRB2 HCK MAP3K10 NEDD4 NEDD4L OIP5 PSMA7 RIN1 SIVA1 SORBS2 TPD52L1 TRIP10
Entrez ID 9610 27
HPRD ID 05813 01259
Ensembl ID ENSG00000174791 ENSG00000143322
Uniprot IDs Q13671 P42684
PDB IDs 2ECD 2KK1 2XYN 3GVU 3HMI 3ULR 4EIH
Enriched GO Terms of Interacting Partners?
Tagcloud ?
abcc12  braf  dabrafenib  deregulated  deserve  detoxification  discover  exploratory  highlighted  invasiveness  klf17  melanoma  mtefd1  nqo1  peaks  rbm10  responder  responders  seldi  silico  slain1  strongest  surrogates  tox3  tspo2  v600  vemurafenib  z  zbtb44 
abl1  adding  amenable  charities  crizotinib  crlf2  csf1r  dasatinib  epor  etv6  flt3  funded  fusions  il7r  lebanese  lymphoblastic  ntrk3  pdgfrb  ph  philadelphia  ptk2b  rearrangements  responsiveness  ruxolitinib  sh2b3  syrian  tslp  tyk2  undefined 
Tagcloud (Difference) ?
abcc12  braf  dabrafenib  deregulated  deserve  detoxification  discover  exploratory  highlighted  invasiveness  klf17  melanoma  mtefd1  nqo1  peaks  rbm10  responder  responders  seldi  silico  slain1  strongest  surrogates  tox3  tspo2  v600  vemurafenib  z  zbtb44 
abl1  adding  amenable  charities  crizotinib  crlf2  csf1r  dasatinib  epor  etv6  flt3  funded  fusions  il7r  lebanese  lymphoblastic  ntrk3  pdgfrb  ph  philadelphia  ptk2b  rearrangements  responsiveness  ruxolitinib  sh2b3  syrian  tslp  tyk2  undefined 
Tagcloud (Intersection) ?